Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a belantamab mafodotin sub-study in relapsed/refractory multiple myeloma, including monotherapy and combinations with nirogacestat, po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Nirogacestat (nirogacestat)
• Pomalyst (pomalidomide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING